Amniotics Investor Relations Material
Latest events
Q2 2024
20 Aug, 2024
Q4 2023
22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Amniotics
Access all reports
Amniotics AB is a Swedish biotechnology company focused on developing stem cell-based therapeutics for severe, life-threatening diseases. The company specializes in mesenchymal stem cells (MSCs) derived from amniotic fluid, which are used to create targeted treatments for various conditions. Amniotics has developed several product candidates, including PulmoStem, aimed at treating lung diseases, CogniStem for central nervous system disorders, NephroStem for kidney conditions, and CutiStem for skin therapies. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
AMNI
Country
🇸🇪 Sweden